Beigene

Beigene Total Assets

The Total Assets of Beigene (6160.HK) as of Nov 20, 2026 is 64.45 B USD. In the previous year, Total Assets was 46.40 B USD — a change of 38.91% (higher).

Total Assets

64.45 BUSD

YoY

38.91%

Last updated:

Total Assets of Beigene is 2025 64.45 B USD. Total Assets of Beigene was 2024 46.40 B USD. It decreases by 38.91% higher compared to the previous year.

The Beigene Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2018
17.63 B USD
Jan 1, 2019
12.63 B USD
Jan 1, 2020
6.47 B USD
Jan 1, 2021
67.75 B USD
Jan 1, 2022
49.99 B USD
Jan 1, 2023
45.49 B USD
Jan 1, 2024
46.40 B USD
Jan 1, 2025
64.45 B USD
The Beigene Total Assets history
YEARTotal AssetsYoY
64.45 BUSD+38.91%
46.40 BUSD+1.99%
45.49 BUSD-9.00%
49.99 BUSD-26.22%
67.75 BUSD+946.76%
6.47 BUSD-48.77%
12.63 BUSD-28.33%
17.63 BUSD+114.98%
8.20 BUSD+157.87%
3.18 BUSD+247.55%
914.99 MUSD+117.76%
420.19 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Beigene Stock analysis

What does Beigene do? Beigene Ltd is a Chinese biotech company that is active in cancer research. It was founded in 2010 by experienced biotech manager John Oyler. The company is now listed on NASDAQ and also has a presence in the United States. Beigene's business model is to develop and distribute innovative cancer treatments. The company utilizes its extensive expertise in molecular and cellular biology as well as clinical development. The goal is to develop therapies that specifically target tumor cells while sparing healthy tissue. This is intended to improve patient survival rates and quality of life. Beigene specializes in the development of cancer treatments, particularly immunotherapies and precision medicine. The latter utilizes targeted attacks against tumor cells at the molecular level to achieve the most focused and effective treatment possible. The company focuses primarily on rare tumor types for which there are currently few or no effective therapies. Beigene is divided into several divisions that focus on different treatment approaches. One important division is immunotherapies, which activate the patient's own immune system against the tumor. Beigene develops antibodies, for example, that recognize and attack specific tumor cells. CAR-T cell therapy is also part of the company's portfolio. In this approach, the patient's T cells are harvested, genetically modified, and multiplied in the laboratory. These T cells are then reintroduced into the patient's body, where they target the tumor specifically. Another division of Beigene is the so-called small molecule drugs. These are chemical compounds that are introduced into the body and specifically attack tumor cells. Beigene develops inhibitors, for example, that inhibit specific enzymes and thus suppress the growth of cancer cells. Beigene has been particularly successful with its drug Zanubrutinib, which is used to treat lymphomas. The drug has achieved excellent results in clinical trials and has already been approved in several countries. Overall, Beigene is an innovative and promising biotech company that specializes in the development of new cancer treatments. The company has a strong expertise in molecular biology and has already achieved promising successes. With its various divisions and products, Beigene covers a wide range of treatment approaches and is likely to play an important role in the fight against cancer in the future. Beigene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Beigene stock

Total Assets of Beigene is 64.45 B USD in 2025.

Total Assets of Beigene changed from 46.40 B USD to 64.45 B USD, representing a 38.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets Beigene since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's Beigene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Beigene

All Key Metrics — Beigene